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Currently the molecular basis for the clinical heterogeneity of X-linked adrenoleukodystrophy (X-ALD) is
poorly understood. The genetic bases for all different phenotypic variants of X-ALD are mutations in the
gene encoding the peroxisomal ATP-binding cassette (ABC) transporter, ABCD1 (formerly adrenoleuko-
dystrophy protein, ALDP). ABCD1 transports CoA-activated very long-chain fatty acids from the cytosol
into the peroxisome for degradation. The phenotypic variability is remarkable ranging from cerebral
inﬂammatory demyelination of childhood onset, leading to death within a few years, to adults remaining
pre-symptomatic through more than ﬁve decades. There is no general genotypeephenotype correlation
in X-ALD. The default manifestation of mutations in ABCD1 is adrenomyeloneuropathy, a slowly pro-
gressive dying-back axonopathy affecting both ascending and descending spinal cord tracts as well as in
some cases, a peripheral neuropathy. In about 60% of male X-ALD patients, either in childhood (35e40%)
or in adulthood (20%), an initial, clinically silent, myelin destabilization results in conversion to a
devastating, rapidly progressive form of cerebral inﬂammatory demyelination. Here, ABCD1 remains a
susceptibility gene, necessary but not sufﬁcient for inﬂammatory demyelination to occur. Although the
accumulation of very long-chain fatty acids appears to be essential for the pathomechanism of all
phenotypes, the molecular mechanisms underlying these phenotypes are fundamentally different. Cell
autonomous processes such as oxidative stress and energy shortage in axons as well as non-cell
autonomous processes involving axoneglial interactions seem pertinent to the dying-back axonop-
athy. Various dynamic mechanisms may underlie the initiation of inﬂammation, the altered immune
reactivity, the propagation of inﬂammation, as well as the mechanisms leading to the arrest of inﬂam-
mation after hematopoietic stem cell transplantation. An improved understanding of the molecular
mechanisms involved in these events is required for the development of urgently needed therapeutics.
 2013 The Authors. Published by Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction and clinical aspects of X-ALD pathophysiology
X-linked adrenoleukodystrophy (X-ALD; OMIM, phenotype
MIM number #300100) is the most common inherited peroxisomal
disorder. The combined incidence of hemizygotes (all phenotypes)
plus heterozygous female carriers is 1:16,800 newborns [1]. One of
the key clinical symptoms during aging of X-ALD patients is asporter subfamily D; AMN,
odystrophy; HSCT, hemato-
chain fatty acids; X-ALD, X-
t (J. Berger).
investigators, clinicians and
enoleukodystrophy.
r Masson SAS. Open access under CC BY-slowly progressive axonopathy affecting sensory ascending and
motor descending spinal cord tracts with 100% penetrance in men
and 65% in heterozygous women by the age of 60 years [2]. Thus, X-
ALD represents one of the most common monogenetically inheri-
ted neurodegenerative diseases.
The progressive dying-back axonopathy represents the core
clinical feature of adrenomyeloneuropathy (AMN) in male patients,
with onset usually between 20 and 30 years and in heterozygous
females with onset between 40 and 50 years. The initial symptoms
include progressive stiffness and weakness of the legs, impaired
vibration sense in the lower limbs, sphincter disturbances and
impotence, as well as scarce scalp hair (alopecia). About 66% of
male AMN patients, but less than 5% of female patients, have
adrenocortical insufﬁciency (Addison disease). Abnormal MRI sig-
nals of white matter in the centrum ovale, pyramidal tracts in the
brainstem and internal capsules have frequently been observed in
AMN, but no gadolinium enhancement is present indicating an
intact bloodebrain barrier and the absence of an acute inﬂamma-
tory process [3].NC-ND license.
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tients, rapidly progressive, inﬂammatory cerebral demyelination
(cerebral X-ALD, CALD) occurs independent of AMN. The onset of
inﬂammation is most common in children (35e40%), before onset
of AMN, and less frequent (20%) in adolescents or adults. The in-
ﬂammatory demyelination starts most often in the midline of the
corpus callosum and progresses relentlessly outward as symmetric,
conﬂuent lesion in both hemispheres. Clinically, this coincides with
a progressive neurologic decline, leading to a vegetative state or
death within 3e5 years. Occasionally, a spontaneous arrest of ce-
rebral disease has been observed. Hematopoietic stem cell trans-
plantation or ex vivo gene correction of autologous hematopoietic
stem cells can arrest the inﬂammation in early stages and, thus,
provide an efﬁcient treatment for the inﬂammatory form of X-ALD
[4e6]. For pathophysiological considerations, it is important to note
that acute inﬂammation is only observed in the central nervous
system (CNS) and not in other tissues of X-ALD patients [3].
In females, cerebral disease is exceedingly rare and has only
been veriﬁed in a casewhere both X chromosomeswere affected. In
an 8-year-old girl with severe CALD, genetic analysis revealed a de
novo Xq27-ter deletion on the paternal X-chromosome in addition
to the maternally inherited ABCD1 mutation [7]. Approximately
65% of heterozygous females develop an AMN-like syndrome with
an average onset later than in the male patients [8]. In addition,
female heterozygotes report prominent diffuse pain and are often
misdiagnosed with ﬁbromyalgia. Investigations in blood leukocytes
reported a “skewed X-inactivation” in 68% of 22 X-ALD carriers with
a signiﬁcant correlation between the extent of the skewing and the
severity of neurologic abnormalities [9]. We hypothesize that the
ameliorated symptoms in the majority of heterozygous female
carriers compared to male patients are due to the X-inactivation
patterns in oligodendrocytes and microglia/macrophages. Here the
population of cells bearing the normal allele may provide enough
functional ABCD1 activity to protect from CALD. When in female
heterozygotes symptoms exceed those of AMN, other explanations
should be sought [7,10]. The importance of the proportion of cells
carrying a healthy allele is emphasized by the observation that in
two CALD patients the arrest of inﬂammation by autologous he-
matopoietic stem cell gene therapy could be achieved by long-term
correction of only about 16% of CD34þ-derived cells, as determined
by ABCD1-positivity of peripheral granulocytes, monocytes, T and B
cells [5,6].
2. Biochemical and genetic aspects of X-ALD pathophysiology
Saturated, unbranched very long-chain fatty acids (VLCFA; fatty
acyl-chain length of 22 carbons) are degraded in the peroxisomal
matrix by the sequential reactions of the enzymes (acyl-CoA oxi-
dase 1, D-bifunctional protein and either peroxisomal b-ketothio-
lase 1 or sterol carrier protein x) of the b-oxidation pathway. In X-
ALD patients, saturated VLCFA, in particular C26:0, accumulate in
tissues and body ﬂuids serving as a diagnostic marker for X-ALD [3].
In all X-ALD patients, mutations affecting the ATP-binding
cassette (ABC) transporter subfamily D member 1 (ABCD1) gene,
located at chromosome Xq28, have been identiﬁed [11]. A sum-
mary of more than 643 different ABCD1 mutations can be found
at the web page http://www.x-ald.nl [12]. The ABCD1 gene en-
codes the peroxisomal ABC half-transporter ABCD1 (formerly
adrenoleukodystrophy protein, ALDP). The ATP-binding domain
of ABCD1 is facing the cytosol and substrates are transported
from the cytosol into the peroxisome under ATP consumption. It
is not clear what determines the substrate speciﬁcity of the
peroxisomal ABC transporters. For the human ABCD1 protein,
CoA-activated VLCFA, such as C26:0-CoA or C24:0-CoA but also
C22:0-CoA, are valid substrates; and the degradation of thesefatty acids by peroxisomal b-oxidation is strongly reduced in
cultured X-ALD ﬁbroblasts [13e15]. In ﬁbroblasts, the peroxi-
somal import and degradation of C26:0-CoA could be blocked
using anti-ABCD1 antibodies [15].
In addition to ABCD1, two other ABC transporters, ABCD2 and
ABCD3, are localized in the peroxisomal membrane [16e18]. The
functional unit of the ABCD1 transporter is a dimer; in vivo, in the
peroxisomal membrane, apparently predominantly homodimers
are formed, although also heterodimers with ABCD2 or ABCD3, the
other two peroxisomal members of the ABCD family are possible
[19]. In all tissues investigated so far, the b-oxidation of VLCFA was
never completely abolished by ABCD1mutations, not even by those
causing a complete loss of function. We could recently show that in
primary ﬁbroblasts of X-ALD patients, the residual activity depends
largely on the homologous peroxisomal ABC transporter ABCD3.
However, ABCD3 was estimated to be about 45 times less efﬁcient
than ABCD1 at mediating a direct or indirect transport of C26:0-
CoA, across the peroxisomal membrane [15], which provides an
explanation why endogenous ABCD3 is unable to rescue the
metabolic defect in X-ALD patients. ABCD2, the closest homolog of
ABCD1, would be expected to compensate more efﬁciently than
ABCD3 but is not expressed at relevant amounts in ﬁbroblasts and,
thus, under normal conditions does not contribute substantially to
the residual b-oxidation activity in this cell type. However, because
ABCD1, ABCD2 and ABCD3 could all contribute, directly or possibly
indirectly (via u-oxidation), to the transport and, therefore, to the
degradation of VLCFA, the extent of the metabolic deﬁciency in
X-ALD probably differs according to the cell type-speciﬁc expres-
sion proﬁles of the three peroxisomal ABC transporters (see
Chapter 4 of this review).
The lack of a generalized genotypeephenotype correlation in X-
ALD becomes clear from three major ﬁndings: i) the same ABCD1
mutation can lead to all possible clinical phenotypes within a single
kindred [20]; ii) a complete loss of ABCD1 protein (e.g. early
frameshift, nonsense mutations or large deletions); as well as iii)
the most common mutation (a two-base pair deletion at
c.1415_16delAG in exon 5), has been found in patients with the
entire clinical spectrum of X-ALD [21]. However, this does not
exclude that individual mutations, which lead to a stable and
correctly localized protein that can form dimers and mediate re-
sidual transporter activity, can be exclusively associated with the
AMN phenotype [22,23].
Interestingly, conventional dietary restriction of VLCFA in X-ALD
patients did not lower plasma C26:0 levels [3]. Subsequent studies
have demonstrated that the accumulated VLCFA in X-ALD are
partially absorbed from the diet but predominantly result from
endogenous synthesis through elongation of long- and very long-
chain fatty acids [24]. Moreover, it was demonstrated that this
elongation system is induced, at least in ﬁbroblasts, of X-ALD pa-
tients [24]. This would explainwhy C22:0 does not accumulate, and
often is even slightly reduced, in tissues and cells of X-ALD patients,
in spite of the fact that C22:0-CoA is an excellent substrate for
ABCD1 [15].
3. Lipidomic aspects of the pathophysiology of X-ALD
In X-ALD, the elongated and insufﬁciently degraded fatty acids
lead to abnormally high levels of VLCFA in various tissues and
body ﬂuids. The increased intracellular concentration of VLCFA-
CoA esters promotes the incorporation of VLCFA into different
complex lipids, where they are normally not enriched. The sub-
strate speciﬁcity of different lipid metabolizing enzymes de-
termines the amount of incorporated VLCFA. This varies among
different cell types and, importantly, between gray and white
matter, thereby effecting crucial regional variation in VLCFA
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brains of CALD cases, a 39fold excess of C26:0 was found in the
phosphatidylcholine fraction compared with white matter tissue
of controls [25]. Also an excess of C30:0, C32:0 and C34:0 was
found in this lipid fraction [26]. In other phospholipids, such as
ethanolamines or serines in the cholesterol ester fraction or in
triglycerides, C26:0 levels were either normal or less than twofold
elevated in unaffected white matter. VLCFA may be selectively
enriched in the ganglioside fraction of white but not gray matter
of X-ALD patients. This is of particular interest as myelin sheaths
contain speciﬁc gangliosides, such as GM4, that are essentially
absent in the remaining human body. Given that inﬂammation in
X-ALD is localized within the CNS e although VLCFA accumulate
in other tissues as well, it is tempting to speculate that a rela-
tionship exists between VLCFA in oligodendrocyte-speciﬁc lipids
and sites vulnerable to inﬂammation.
The lipid proﬁle of X-ALD brain tissue changes drastically when
actively demyelinating regions are investigated. Within such areas,
VLCFA are strongly enriched in cholesterol esters [25,27]. It is
believed that the cholesterol esters containing VLCFA are pre-
dominantly located in invading monocytes/macrophages, entering
the CNS after the opening of the bloodebrain barrier occurs, and
within activated microglia [28]. ABCD1 deﬁcient macrophages/
microglia are unable to degrade VLCFA from phagocytosed myelin
debris during the inﬂammatory demyelinating process. The unde-
graded VLCFA are then stored as cholesterol esters, which can even
form crystalline needles inside these cells, contributing to cellular
stress.
Another important issue concerning the pathophysiology of X-
ALD is thehigh concentrationofVLCFA in lyso-phosphatidylcholines,
resulting from the degradation of phosphatidylcholine viahydrolysis
of the fatty acid from the sn-2 position by phospholipase 2A. VLCFA-
containing lyso-phosphatidylcholine has been demonstrated to
induce microglia apoptosis and macrophage recruitment from the
periphery [29]. In fact, 1-hexacosanoyl-2-lyso-sn-3-glycero-phos-
phorylcholine (26:0-lyso-PC) is a diagnostic marker for X-ALD; and
this metabolite is now used in prenatal analysis and newborn
screening for X-ALD at the Kennedy Krieger Laboratory and Mayo
Clinic [30].
4. Functional redundancy of ABC transporters and their role
in the pathophysiology of X-ALD
Inherited defects in the peroxisomal transporter ABCD1 is the
underlying genetic defect in X-ALD. Thus, the expression level of
ABCD1 in different tissues and cell types is of utmost importance
for the understanding of the pathology. Interestingly, ABCD1 is
rather weakly expressed in the CNS compared to other tissues
such as heart, skeletal muscle, liver, kidney or endocrine glands
[31,32]. By immunohistochemical analyses, the highest expression
level of ABCD1 in the CNS was detected in microglia, astrocytes
and epithelial cells, whereas different populations of oligoden-
drocytes in the subcortical white matter and cerebellum were
described with high, low or undetectable levels of ABCD1 [31]. In
most neuronal populations, ABCD1 is barely expressed, with the
exception of certain neurons in the hypothalamus, the basal nu-
cleus of Meynert, periaqueductal gray matter and locus coeruleus
[32]. With regard to the pathomechanism of the spinal cord
axonopathy and sensory neuropathy in AMN, it is striking that
ABCD1 is highly expressed in the dorsal root ganglion [32].
Interestingly, many cell populations or tissues in the human body
that express high levels of proopiomelanocortin (POMC), such as
the pituitary gland, dorsal root ganglion, adrenocortical cells,
distal tubules of the kidney, liver and skin, also express high levels
of ABCD1 [32,33].In the target tissues of X-ALD, rather complementary expression
patterns have been described for the peroxisomal ABC transporters
ABCD1 and ABCD2 [34,35]. For example, in the adrenal gland,
ABCD1 is strongly expressed in the cortex but is not detectable in
the medulla. Conversely, ABCD2 is strongly expressed in the me-
dulla but not in the cortex. Interestingly, the adrenal pathology in
X-ALD is restricted to the cortex, where degeneration leads to
Addison disease in X-ALD patients.
Overexpression of ABCD2 and, to a lesser extent, ABCD3 can
correct themetabolic defect in ﬁbroblasts of X-ALD patients [36,37].
A mouse model for X-ALD was independently generated in three
laboratories by targeted disruption of the Abcd1 gene [38e40]. In
Abcd1 deﬁcient mice VLCFA accumulate in all tissues analyzed
including brain, spinal cord, adrenal gland, skeletal muscle, kidney,
and testis [38e41]. A late-onset neurological phenotype develops
at about 18e20 months, with moderate axonal degeneration in the
long tracts of the spinal cord but without inﬂammatory cerebral
demyelination; thus, this mouse model is reminiscent of AMN
[42,43], although adrenal insufﬁciency could not be demonstrated
[44]. By transgenic ubiquitous overexpression of ABCD2, the
biochemical defect and the neurological phenotype of the Abcd1-
deﬁcient mice could be rescued [45].
Thus, we hypothesize that the expression levels of ABCD2 e and
to a lower extent possibly ABCD3 e contribute to the metabolic
manifestation of ABCD1 deﬁciency in different cell types. Yet as-
sociation studies have demonstrated that allelic variations of
ABCD2 or ABCD3 are unlikely to be involved in the clinical hetero-
geneity of X-ALD [46,47].
5. Pathophysiology of AMN in males and in heterozygous
females
AMN represents the core clinical syndrome in X-ALD. The main
symptoms are adrenal insufﬁciency, gait difﬁculties and bowel and
bladder problems [48,49]. The neurological symptoms are related
to a myeloneuropathy. Adrenal insufﬁciency appears independent
of the myeloneuropathy in about two-thirds of the AMN patients;
there is no correlation between the duration or severity of endo-
crine dysfunction and the severity of the myeloneuropathy [48].
The age at onset as well as the rate of progression of the dying-back
axonopathy can vary dramatically. In male AMN patients, the
earliest onset of neurologic symptoms, with 12 years, has been
described in an AMN patient collective of the Kennedy Krieger
Institute; the mean age of onset in this cohort was 28 years and the
latest was 60 years [50]. The molecular basis for this variability is
currently unknown but seems to be independent of the nature of
the ABCD1 mutation; therefore the time of onset is unpredictable
for pre-symptomatic patients. The individual genetic background
(modiﬁers) may contribute to the broad spectrum. Neurotrophic
factors such as ciliary neurotrophic factor (CNTF) or brain-derived
neurotrophic factor (BDNF) are candidates.
Histological analyses of the dorsal root ganglia from AMN pa-
tients did not show apparent neuronal loss, necrosis or apoptosis
[49]. Morphometric studies, however, revealed neuronal atrophy
with a decrease in the number of large neurons and a corre-
sponding increase in neurons less than 2000 mm2 [49]. Many
mitochondria in AMN neurons demonstrate lipid inclusions at the
ultrastructural level, raising the possibility that, in addition to the
peroxisomal defect, impaired mitochondrial function may
contribute to the myelopathy through a failure of ATP-dependent
axonal transport in AMN spinal tracts with consequent dying-
back axonal degeneration [51].
The issue of mitochondrial alterations in X-ALD has been
intensely investigated in the Abcd1-deﬁcient mouse model, where
impaired oxidative phosphorylation has been observed in the
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relative increase in accumulation of VLCFA is comparable in these
tissues [41,52]. The reasons for mitochondrial dysfunction in some
cell types but not in others, in spite of a similar extent of accu-
mulation of VLCFA, could be: i) differences in the lipid species
containing VLCFA (as discussed in Chapter 3 of this review); ii)
different susceptibility of mitochondria to VLCFA in different cell
types; iii) functional characteristics of vulnerable cell types, such as
the dorsal root ganglion cell; or iv) a combination thereof. In the
Abcd1-deﬁcient mouse model, lipid peroxidation causes oxidative
damage, as evidenced by N-malondialdehyde-lysine concentra-
tions. This was observed already at the age of 3.5 months, long
before the ﬁrst neuropathological lesions in the spinal cord are
detectable [53]. In addition, an activation of anti-oxidative
responses was observed in organotypic spinal cord slices of
Abcd1-deﬁcient mice after exposure to exogenous VLCFA [53].
Interestingly, a treatment of Abcd1-deﬁcient mice with a mixture of
antioxidants consisting of N-acetyl-cysteine, a-lipoic acid and
a-tocopherol reversed the oxidative damage, the axonal degener-
ation, as well as the locomotor impairment in bar cross and
treadmill tests [54,55].
In plasma and blood cells of human X-ALD patients of either
AMN or CALD phenotype, signs of oxidative stress have been
detected [56,57]. In two independent studies, normal mitochon-
drial functions were observed in primary human X-ALD ﬁbroblasts
under normal culturing conditions [41,52]. However, when the
ﬁbroblasts were exposed to 50 mM C26:0, a slight but signiﬁcant
decrease of oligomycin-sensitive respiration, which is indicative of
the activity of the mitochondrial Hþ-ATP synthase, was observed
[52]. Also oxidative stress could be increased in human ﬁbroblasts
by the application of VLCFA [53]. Lopez-Erauskin and colleagues
postulated a model, in which an excess of C26:0 induces mito-
chondrial production of reactive oxygen species leading to mito-
chondrial oxidative damage to DNA and proteins, inefﬁcientHigh penetrance at advanced age
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Fig. 1. Hypothetical model and pathology of AMN; (A) Model showing the sequential even
Quantitative magnetization transfer characteristics of the human cervical spinal cord in a se
dorsal and lateral columns (Image was provided by Dr. Ali Fatemi, Department of Neurogene
(C) Anti-phosphorylated neuroﬁlament immunostaining of the cervical spinal cord of an AMN
from J. Neuropathol. Exp. Neurol.; Powers et al., 2000; 59:89e101). (D) T2-weighted magnet
lesions in the corticospinal tract.oxidative phosphorylation and ﬁnally to dying-back axonopathy
[52]. In vitro, cytotoxicity of VLCFA has been demonstrated for oli-
godendrocytes, astrocytes and neurons [58]. In these primary cul-
tures, 20 mM C22:0, C24:0 and C26:0, but not C16:0, caused cell
death in 24 h, with VLCFA being most toxic to myelin-producing
oligodendrocytes.
Given the expression pattern of ABCD1 in the nervous system, it
seems likely that a non-cell autonomous process is at work.
Oligodendrocyteeaxonal interaction may be disturbed and
constitute a primary trigger for axonal degeneration, oxidative
stress and mitochondrial dysfunction in the axons of AMN patients.
One argument along this line, is the observation that mice lacking
functional peroxisomes only in neurons do not develop axonal
degeneration [59]. Also selective deﬁciency of peroxisomes in oli-
godendrocytes leads to early axonal loss and neuroinﬂammation in
the absence of demyelination [60]. Recent ﬁndings have demon-
strated that peroxisomal impairment in Schwann cells of agedmice
causes physically unstable paranodal loops that develop swellings
ﬁlled with vesicles and electron-dense material [61,62]. This novel
model of a demyelinating neuropathy demonstrates that peroxi-
somes serve important functions in the peripheral myelin
compartment, required for long-term axonal integrity. A similar
mechanism could also contribute to mitochondrial damage and
oxidative stress resulting in the dying-back axonopathy seen in
AMN. This vicious cycle underlying the pathophysiology of AMN is
depicted in Fig. 1A: disturbances in myelineaxon interaction are
both the cause and consequence of mitochondrial dysfunction,
ultimately resulting in the dying-back axonopathy. The axonopathy
in the dorsal and lateral columns can be visualized using magne-
tization transfer imaging in severely affected patients with AMN
(Fig 1B and Ref. [63]). Post mortem the severe atrophy of the lateral
columns of the cervical spinal cord of AMN patients can be seen by
immunostaining using antibodies against phosphorylated neuro-
ﬁlament (Fig 1C [48]). In some cases, symmetric lesions in thedative 
ress
hondrial 
unction
D
C
B
ts leading to the dying-back axonopathy, the main clinical manifestation of AMN. (B)
verely affected patient with AMN. The arrows indicate the signal hyperintensity in the
tics, The Kennedy Krieger Institute, Johns Hopkins Medical Institutions, Baltimore, USA).
patients showing atrophy of the lateral columns (arrows; reproduced with permission
ic resonance image of the brain in an AMN patient. The arrows indicate the symmetric
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(Fig 1D).
6. Pathophysiology of inﬂammation in cerebral X-ALD
New and old concepts suggest that the inability to efﬁciently
degrade VLCFA, as well as the incorporation of VLCFA into different
complex lipids, is directly involved in the pathology of the cerebral
inﬂammatory form of X-ALD. However, different mechanisms seem
to be involved in: i) the initial cerebral demyelination; ii) the spo-
radic conversion to rapidly progressive inﬂammatory demyelin-
ation; iii) the environmentally mediated conversion from pure
AMN to rapidly progressive inﬂammatory demyelination; and iv)
the inability to arrest inﬂammation by intrinsic mechanisms or
anti-inﬂammatory therapeutic strategies. No differences in these
mechanisms have been observed when comparing childhood and
adult cerebral forms of X-ALD. Thus, all inﬂammatory variants of
X-ALD are referred to as CALD within this chapter.
The initiation of cerebral demyelination could well be directly
related to the amount of VLCFA in complex lipids, such as phos-
phatidylcholines, sulfatides or gangliosides. Studies in artiﬁcial
phospholipid vesicles suggest that the accumulation of VLCFA in
myelin could lead to progressive destabilization of myelin sheaths
and subsequent demyelination [3,64]. Thus, this initial phase of
spontaneous onset of demyelination might be directly related to
the level of VLCFA in the myelin sheath. Although VLCFA levels in
blood or cultured ﬁbroblasts are indistinguishable in X-ALD pa-
tients with different clinical phenotypes, the amounts of VLCFA
were found to be higher in normal appearing white matter of CALD
patients compared with AMN patients [65]. In addition, oligoden-
drocytes derived from induced pluripotent stem cells of patients
with CALD accumulated more VLCFA than those derived from AMN
patients [66].
The demyelination typically begins in the center of the corpus
callosum, where the white-matter ﬁber bundles are the most
tightly packed, and spreads outward into the periventricular white
matter [67,68]. Genetic segregation analysis provided support for
the hypothesis that autosomal genes play a role in the clinical
manifestation of X-ALD [50,69,70]. Thus, polymorphisms in genes
involved in the different pathways, through which excess levels of
VLCFA are redistributed into various lipid species, may play a role in
this initial phase of cerebral demyelination. As the majority of
VLCFA are derived from endogenous synthesis, the enzymes
involved in this pathway such as the elongases of very long-chain
fatty acids, ELOVL6 or ELOVL1, are other candidates [71,72]. Thus,
it might be a matter of time, the amount of VLCFA in different lipids
and/or stochastic factors that determine whether or not and when
spontaneous myelin breakdown occurs. In approximately 10e15%
of patients that develop cerebral demyelination the demyelinating
process halts spontaneously. In these cases contrast enhancement
is not seen, and disruption of the bloodebrain barrier does not
occur [73].
However, in the majority of cases this initial cerebral demye-
lination converts into a rapidly progressive inﬂammatory demye-
lination, opening of the bloodebrain barrier and invasion of
mononuclear cells predominantly macrophages, many of which
contain myelin degradation products [3]. The lesion progresses
rapidly in a parieto-occipital distribution in about 80% of cases or in
a fronto-parietal distribution in the remaining 20% of cases. The
molecular mechanisms responsible for the conversion into full
blown inﬂammation are only poorly understood. It has been shown
that decreased brain magnetic resonance perfusion precedes
leakage of the bloodebrain barrier [74]. This invites speculation on
the contribution of blood volume and vascular density to the
pathogenesis of demyelination as it has been discussed for decadesin the ﬁeld of multiple sclerosis [75e77]. Another important factor
might be that lyso-phosphatidylcholine with incorporated VLCFA
can lead to microglial activation and apoptosis [29]. It has been
suggested that microglial dysfunction strongly contributes to
neuroinﬂammation and possibly alters the neurovascular unit.
Elevated levels of proinﬂammatory chemokines (IL-8, IL-1ra, MCP-
1, MIP-1b) have been observed in the cerebrospinal ﬂuid of CALD
patients and correlatewith theMRI severity [78]. Areas nearby sites
where the bloodebrain barrier is disrupted, show inﬁltration of T
cells, mostly CD8 cytotoxic T cells (a/b TCR positive), and, less
frequent, B cells into morphologically unaffected white matter
[68,79]. This T and B cells invasion beyond the active lesion is
strongly suggestive of an immune attack. Cytolysis, rather than
apoptosis, appears to be the major mode of oligodendrocytic death
[79]. A recent article demonstrated that primary oligodendrocyte
death does not elicit anti-CNS immunity [80]. However, these ex-
periments were performed without excess of VLCFA. CD1 mole-
cules, the major MHC-unrestricted lipid antigen presenters, have
been observed most prominently within the acute CALD lesion.
Interestingly, in particular lipid antigens containing VLCFA, as for
example gangliosides, have altered immunological properties
[81,82]. As discussed in Chapter 3 of this review, some gangliosides
are brain-speciﬁc, which would explain why there is no inﬂam-
matory reaction in other affected tissues in X-ALD patients, such as
peripheral nerve, adrenocortical cells or Leydig cells in the testis.
However, also proteolipid protein, a highly abundant protein of
myelin, contains VLCFA and might be a candidate antigen for elic-
iting auto immunity following myelin breakdown in CALD.
There are several reports that a moderate or severe head
trauma can initiate the conversion to rapidly progressive inﬂam-
matory demyelination [83e85]. In some of these cases, demye-
lination started at the site of the original contusion [83e85]. This
again emphasizes the importance of bloodebrain barrier integrity
in X-ALD. It is possible that an increased permeability of the
bloodebrain barrier enhances the recognition of VLCFA-containing
antigens such as proteolipid protein or gangliosides, possibly
involving CD1 lipid presentation. Head trauma represents only one
of several potential environmental factors that can trigger the
cerebral phenotype in patients genetically at risk for CALD. The
observation that monogenetic twins can present with discordant
phenotypes underlines the importance of epigenetic, environ-
mental and stochastic factors in the process of CALD [86].
Allogeneic hematopoietic stem cell transplantation (HSCT) is the
only therapeutic approach that can arrest inﬂammatory cerebral
demyelination ewhen performed at an early stage of disease [6]. It
is important to mention that in contrast to HSCT performed for
lysosomal CNS diseases, there is no cross-correction of other cell
types after HSCT in X-ALD because ABCD1, as a peroxisomal mem-
brane protein cannot be released. Themechanismof HSCT-mediated
arrest of the brain inﬂammation in X-ALD is currently not clear.
However, the success of HSC gene therapy indicates that only partial
correction of the HSC progeny is necessary to halt cerebral disease
[5,6]. It is also important to note that after the transplantation
procedure, demyelinating lesions continue to expand, usually for
12e18 months, before the progression is arrested [6].
Within the active lesion, oxidative stress has been observed in
activated astrocytes and macrophages [87]. The immunoreactivity
of oxidative stress markers (manganese-superoxide dismutase, 4-
hydroxynonenal, malondialdehyde) tended to vary directly with
the degree of inﬂammation and myelin breakdown [87]. Invading
macrophages and activated microglia cells accumulate VLCFA
probably originating from the phagocytosed myelin. As already
shown by Schaumburg and coworkers in 1975, this leads to an
accumulation of ultrastructural cytoplasmic needle-like crystal-
line inclusions, later described to consist of VLCFA-containing
Clinical 
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Proinflammatory 
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VLCFA-mediated 
myelin membrane 
instability
Refractory to anti-
inflammatory 
therapies
Spontaneous or 
induced 
demyelination
Intrinsic defects 
of
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Spontaneous 
arrest of 
inflammation
Likelihood of CALD decreases with age
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Inability to 
suppress 
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Fig. 2. Hypothetical model showing the sequential events leading to the inﬂammatory demyelination in CALD. The inset images are characteristic MRI features of a boy afﬂicted by
CALD. The left panel shows a T2-weighted image with a symmetric and conﬂuent demyelinating lesion within the parieto-occipital lobes. The right panel shows a T1-weighted
image post gadolinium administration. Gadolinium enhancement indicates active inﬂammation and disruption of the blood brain barrier.
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aggregates inﬂuence immune functions, such as cytokine secre-
tion, and might be incompatible with the generation of an
anti-inﬂammatory milieu. It may thus not be surprising that
traditional anti-inﬂammatory therapy has failed. The apparent
cytotoxicity of lyso-phosphatidylcholine containing VLCFA for
macrophages and microglia may additionally be of critical
importance [29]. The invasion of macrophages and possibly cross-
trafﬁcking of monocytes may be the reason for success of HSCT.
Inﬂammatory demyelination andmicroglial cell death provides an
opportunity for long-term repopulation of the brain parenchyma
with residential macrophages/microglia derived from peripheral
stem cell progenitors [6,88,89], although other non-cell mediated
mechanisms may also be at play. A hypothetical model showing
the sequential events leading to the inﬂammatory demyelination
in CALD is depicted in Fig. 2.7. Pathophysiology of adrenals, testis and hair in X-ALD
ABCD1 protein is present in the adrenal cortex but not in the
adrenal medulla [32,33], while ABCD2 shows the opposite distri-
bution [34]. This is in good agreement with the pathological ﬁnd-
ings of lamellae and lamellarelipid proﬁles, which were shown to
contain VLCFA esteriﬁed to cholesterol, in adrenocortical cells [90].
These saturated fatty acids were proposed to be toxic to the adrenal
cortex resulting in apoptotic cell death [90]. There is no evidence
for a reversal of adrenal failure after hematopoietic cell trans-
plantation in X-ALD [91]. However, hormone replacement therapy
successfully manages the adrenal insufﬁciency.
In the testis of X-ALD patients, lamellae and lamellarelipid
proﬁles of VLCFA-cholesterol esters are present in interstitial cells
of Leydig and their precursors and can be seen at an ultrastructural
level. In addition there can be some Leydig cell loss. Degenerative
changes in seminiferous tubules in AMN appear indistinguishable
from those of adult cerebral ALD [90,92]. In a study of 49 AMN
patients an impairment of sexual functions was suffered by 53.8% of
the patients [93]. The majority (81.6%) showed testicular dysfunc-
tions reﬂected by a subnormal testosterone/LH ratio and/or
elevated gonadotropins [93].Hair of AMN patients is typically thin and sparse (alopecia). The
scant scalp hair may be related to the fact that ABCD1 is normally
well expressed in hair follicles [32]. The thinning of scalp hair can
occur as early as in adolescence and does not appear to be pre-
dictive for the neurologic phenotype [94].
8. Concluding remarks
X-linked adrenoleukodystrophy is a genetically and metaboli-
cally well-deﬁned disease that poses challenges in explaining the
clinical heterogeneity of phenotypes. While the presentation of
AMN is the default manifestation of mutations in ABCD1, the ce-
rebral disease cannot be explained by mutations in ABCD1 alone.
Here, ABCD1 remains a susceptibility gene, necessary but not suf-
ﬁcient for inﬂammatory demyelination to occur. The systematic
nature of the inﬂammatory disease raises questions as to the role of
the vascular supply and bloodebrain barrier integrity. We conclude
that in both AMN and CALD, the pathophysiology is a dynamic cell
autonomous and non-cell autonomous process during which,
despite the Mendelian nature of the disease, environmental and
epigenetic factors are crucial. It is important to consider the
fundamentally different molecular mechanisms and cell in-
teractions underlying AMN and CALD while developing novel
therapeutic strategies urgently needed for these phenotypes.
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